The FANCD2 Protein encodes a protein involved in critical cellular processes related to DNA repair and genomic stability. This gene has been studied in the context of neurodegenerative diseases including Parkinson's disease and ALS, as well as various cancer predisposition syndromes. [1]
| FANCD2 Protein | |
|---|---|
| Protein Name | Fanconi anemia group D2 protein |
| Alternative Names | FA-D2, FANCD2 |
| Molecular Weight | 164 kDa |
| Length | 1451 amino acids |
| UniProt ID | [Q9BXW6](https://www.uniprot.org/uniprot/Q9BXW6) |
| Cellular Location | Nucleus (chromatin) |
FANCD2 (Fanconi Anemia Group D2 Protein) is a key effector protein in the Fanconi anemia DNA repair pathway. It plays a critical role in resolving DNA interstrand crosslinks (ICLs) and maintaining genomic stability. Following monoubiquitination by the FA core complex, FANCD2 localizes to chromatin and coordinates DNA repair through homologous recombination and other mechanisms. Dysfunction of FANCD2 leads to Fanconi anemia, a devastating disorder characterized by bone marrow failure, developmental abnormalities, and cancer predisposition.
FANCD2 contains several functional domains:
FANCD2 is monoubiquitinated on Lysine 561 (K561) by the FA core complex (including FANCL E3 ubiquitin ligase). This modification is essential for its function in DNA repair and is activated by DNA damage.
FANCD2 interacts with:
The FANCD2-FANCI heterodimer is the functional core of the FA pathway:
FANCD2 plays a central role in ICL repair:
FANCD2 stabilizes stalled replication forks:
FANCD2-activating compounds being developed:
| Agent | Mechanism | Development Stage |
|---|---|---|
| Curcumin | FANCD2 activation | Preclinical |
| HDAC inhibitors | Upregulate FA pathway | Research |
| Monoubiquitination enhancers | Direct activation | Investigational |
AAV-mediated FANCD2 delivery approaches.
FANCD2-/- mice:
Tissue-specific deletion models show:
FANCD2 overexpression protects against:
FANCD2 dysfunction contributes to:
| Cancer Type | Risk | Mechanism |
|---|---|---|
| Breast | Elevated | Homologous recombination defect |
| Ovarian | Elevated | ICL repair deficiency |
| Leukemia | High | Genomic instability |
| Solid tumors | Variable | FA pathway inactivation |
| Disorder | FANCD2 Association | Evidence |
|---|---|---|
| Parkinson's Disease | Altered expression | Post-mortem studies |
| ALS | Impaired activation | Patient cells |
| Alzheimer's Disease | DNA repair decline | Age-related changes |
Current research priorities:
Taniguchi et al. [FANCD2 monoubiquitination and DNA damage response (2002)](https://doi.org/10.1016/s0092-8674(02). 2002. ↩︎